Method for Producing a Godulbaki Vitamin with Anti-inflammatory, Antihypertensive, Antioxidant, and Anti-cholesterol activities, and the Godulbaki Vitamin

Abstract

The present invention relates to a Godeulppaegi vitamin composition, and more specifically, to a method for manufacturing a Godeulppaegi vitamin and the Godeulppaegi vitamin, wherein Godeulppaegi powder, prepared by cultivating, harvesting, drying, pulverizing, and sterilizing Godeulppaegi to improve its bitter taste and which possesses anti-inflammatory, antihypertensive, antioxidant, and anti-cholesterol activities, is mixed with other nutritional components such as vitamins to form a tablet formulation.

Description

Technology Field

[0001] The present invention relates to a Godeulppaegi vitamin composition, and more specifically, to a method for manufacturing a Godeulppaegi vitamin and the Godeulppaegi vitamin, wherein Godeulppaegi powder, prepared by cultivating, harvesting, drying, pulverizing, and sterilizing Godeulppaegi to improve its bitter taste and which possesses anti-inflammatory, antihypertensive, antioxidant, and anti-cholesterol activities, is mixed with other nutritional components such as vitamins to form a tablet formulation. Background Technology

[0002] Godeulppaegi was formerly called by the Chinese characters Gochae, Godolbi, and Godolchae, which mean a bitter-tasting herb, but it came to be known as Godeulppaegi in the early 20th century.

[0003] Godeulppaegi is a biennial plant belonging to the Asteraceae family and is characterized by a bitter taste due to inulin.

[0004] Inulin is known as natural insulin and regulates blood sugar levels when consumed.

[0005] In addition, Godeulppaegi contains large amounts of saponin and beta-carotene, which inhibit carcinogens and improve gastrointestinal and digestive functions.

[0006] In addition, the various nutrients contained in Godeulppaegi produce effects such as anti-inflammatory, antioxidant, immune system strengthening, detoxification, and improved blood circulation.

[0007] Accordingly, the consumption of Godeulppaegi is actively encouraged.

[0008] However, to date, due to the bitter taste of Godeulppaegi, it is mainly consumed in dishes such as kimchi, seasoned greens, and stir-fries.

[0009] In particular, Godeulppaegi kimchi made from radishes harvested in the autumn is famous as a traditional kimchi of the Jeolla region.

[0010] However, the unique aroma and bitter taste of *godeulppaegi* (a type of wild lettuce) inevitably remain unpopular among children and the younger generation.

[0011] Therefore, there is a need to develop a method for producing Godeulppaegi vitamins that can be chewed and consumed by improving the bitter taste of Godeulppaegi and adding various nutrients. The problem to be solved

[0012] The present invention has been devised to solve the aforementioned problems, and the invention provides a method for manufacturing a sweet-tasting Godeulppaegi vitamin by optimizing the mixing ratio of Godeulppaegi powder (produced by cultivating and processing Godeulppaegi into powder), sugar powder, vitamin C, vitamin and mineral mixed powder, amino acid mixture, seven berry mixed powder, and sweetener mixed powder.

[0013] In addition, the objective of the present invention is to provide a method for manufacturing a Godeulppaegi vitamin in the form of a tablet that can be chewed and consumed. means of solving the problem

[0014] To achieve the above objective, the present invention comprises the steps of cultivating and harvesting Godeulppaegi, washing the harvested Godeulppaegi with water and sun-drying it, hot-air drying the Godeulppaegi, grinding the Godeulppaegi into Godeulppaegi powder, sterilizing the Godeulppaegi powder, the Godeulppaegi powder, a sugar powder composed of glucose and starch hydrolysate, vitamin C powder, calcium phosphate, ferrous fumarate, nicotinamide, zinc oxide, a vitamin and mineral mixed powder composed of vitamin A, vitamin C, vitamin E, vitamin B1 hydrochloride, vitamin B2, vitamin B6 hydrochloride, and folic acid, an amino acid mixed powder composed of L-methionine, L-tryptophan, L-glutamine, L-proline, and glycine, a seven-berry mixed powder composed of blackberry powder, blackcurrant powder, blueberry powder, strawberry powder, raspberry powder, cranberry powder, and acai berry powder, and xylitol, magnesium stearate, A method for manufacturing Godeulppaegi vitamin is provided, comprising the steps of weighing and mixing a sweetener mixture powder consisting of anhydrous citric acid, enzyme-treated stevia, and synthetic flavoring, compressing tablets, and packaging.

[0015] In a preferred embodiment, the composition further comprises: the Godeulppaegi powder in an amount of 1 to 10 weight% relative to the total weight; the sugar powder in an amount of 70 to 75 weight% relative to the total weight; the vitamin C powder in an amount of 4 to 6 weight% relative to the total weight; the vitamin and mineral mixed powder in an amount of 0.005 to 0.02 weight% relative to the total weight; the amino acid mixture in an amount of 0.005 to 0.02 weight% relative to the total weight; the seven berry mixed powder in an amount of 2.5 to 7.5 weight% relative to the total weight; and the sweetener mixed powder in an amount of 10 to 12 weight% relative to the total weight.

[0016] In a preferred embodiment, the washing step comprises washing the Godeulppaegi with water for 5 to 15 minutes and repeating the washing twice, the sun-drying step comprises drying in sunlight for 4 to 6 hours, the hot-air drying step comprises drying at a temperature of 65 to 75°C for 12 to 48 hours, the grinding step comprises grinding the Godeulppaegi after the hot-air drying is completed to a size of 70 to 90 mesh, and the sterilization step comprises sterilizing at a temperature of 90 to 99°C for 12 to 48 hours.

[0017] In a preferred embodiment, the Godeulppaegi comprises having a higher NO (Nitric Oxide) inhibitory activity compared to a positive control treated only with LPS at a concentration of 0.05 to 0.2 mg / mL of the sample containing the Godeulppaegi, exhibiting 60 to 83% ACE (Angiotensin I Converting Enzyme) inhibitory activity at a concentration of 0.2 to 2 mg / mL of the sample containing the Godeulppaegi, exhibiting 10 to 24% DPPH (2,2-Diphenyl-1-picrylhydrazyl) radical scavenging activity at a concentration of 0.5 to 2 mg / mL of the sample containing the Godeulppaegi, and exhibiting 10 to 98% ABTS (2,2'-Azino-bis(3-ethylbenzothiazoline-6-sulfonic acid)) radical scavenging activity at a concentration of 2.5 to 10 mg / mL of the sample containing the Godeulppaegi, and the It further includes having anti-inflammatory, antihypertensive, antioxidant, and anti-cholesterol activities, including exhibiting 6 to 18% anti-cholesterol activity per 0.25 to 0.5 mg / mL of a sample containing Godeulppaegi.

[0018] In addition, the present invention further provides a Godeulppaegi vitamin comprising the above-described method for manufacturing Godeulppaegi vitamin. Effects of the invention

[0019] The present invention has the following effects.

[0020] First, the method for manufacturing Godeulppaegi vitamin according to an embodiment of the present invention has the advantage of being able to produce a chewable vitamin tablet by mixing powder processed from Godeulppaegi that has been directly collected, sown, and harvested.

[0021] In addition, the Godeulppaegi vitamin produced by the method for producing Godeulppaegi vitamin according to an embodiment of the present invention has the advantage of improving the bitter taste of inulin contained in Godeulppaegi, allowing Godeulppaegi to be consumed deliciously.

[0022] In addition, the Godeulppaegi vitamin according to the embodiment of the present invention has the advantage of allowing the intake of other nutrients, such as vitamin C, minerals, amino acids, and xylitol, along with Godeulppaegi. Brief explanation of the drawing

[0023] FIG. 1 is a diagram illustrating a method for manufacturing Godeulppaegi vitamin according to an embodiment of the present invention. FIG. 2 is a drawing showing a photograph of Godeulppaegi vitamin according to an embodiment of the present invention. FIG. 3 is a diagram showing the results of analyzing the vitamin C content contained in Godeulppaegi vitamin according to one embodiment of the present invention using HPLC. FIG. 4 is a diagram showing the results of a microbial test of Godeulppaegi vitamin according to one embodiment of the present invention. FIG. 5 is a diagram showing the anti-inflammatory activity, antihypertensive activity, and antioxidant activity of *Godeulppaegi* according to an embodiment of the present invention. Figure 6 is a diagram showing the anti-cholesterol activity of *Godeulppaegi* according to an embodiment of the present invention. Specific details for implementing the invention

[0024] The terms used in this invention have been selected to be as widely used as possible; however, in specific cases, terms have been arbitrarily selected by the applicant. In such cases, the meaning should be understood by considering the meaning described or used in the detailed description of the invention, rather than merely the name of the term.

[0025] Hereinafter, the technical configuration of the present invention will be described in detail with reference to preferred embodiments illustrated in the attached drawings.

[0026] However, the present invention is not limited to the embodiments described herein and may be embodied in other forms.

[0027] Identical reference numbers throughout the specification represent identical components.

[0029] FIG. 1 is a diagram illustrating a method for manufacturing Godeulppaegi vitamin according to an embodiment of the present invention. According to FIG. 1, the method for manufacturing Godeulppaegi begins by first cultivating and harvesting Godeulppaegi.

[0030] The above Godeulppaegi is harvested by collecting seeds in May from Godeulppaegi that have bloomed in open fields in March and April each year, sowing them in June on land that has been plowed with well-rotted compost, and thinning out the Godeulppaegi that has grown from about 70 days from the day of sowing until mid-November.

[0031] In addition, the method for manufacturing Godeulppaegi vitamin according to the present invention involves preparing Godeulppaegi powder through washing, sun drying, hot air drying, grinding, and sterilization steps to alleviate the bitter taste of the Godeulppaegi, and then mixing it with vitamin C and berry extracts that have a strong sour taste to produce a vitamin product.

[0032] To this end, the method for manufacturing Godeulppaegi vitamin according to the present invention proceeds to the step of washing and sun-drying the harvested Godeulppaegi to process it into powder.

[0033] In addition, the harvested Godeulppaegi is washed with water for 5 to 15 minutes, and the washing process is repeated twice. The washed Godeulppaegi is then sun-dried by drying it in the sun for 4 to 6 hours.

[0034] This is intended to first remove moisture from the Godeulppaegi and to denature or remove the toxins that cause the bitter taste of the Godeulppaegi.

[0035] In addition, the aforementioned sun drying stabilizes the active ingredients of the Godeulppaegi and facilitates storage and preservation.

[0036] Next, the sun-dried Godeulppaegi is hot-air dried at a temperature of 65 to 75°C for 12 to 48 hours.

[0037] Next, the Godeulppaegi, which has been dried to some extent through the above-mentioned sun drying and hot air drying, is ground to a size of 70 to 90 mesh to make Godeulppaegi powder.

[0038] Next, the above Godeulppaegi powder is sterilized at a temperature of 90 to 99°C for 12 to 48 hours.

[0039] In this invention, since the Godeulppaegi powder prepared in advance is used for the production of Godeulppaegi vitamins, the sterilized Godeulppaegi powder is stored in a refrigerator and then taken out and used when producing the Godeulppaegi vitamins.

[0040] Next, sterilized Godeulppaegi powder and other nutritional components such as sugar powder, vitamin C powder, vitamin and mineral mixed powder, amino acid mixed powder, seven berry mixed powder, and sweetener mixed powder are weighed and mixed.

[0041] At this time, it is desirable to mix the sterilized Godeulppaegi powder and the other nutritional components by selecting an optimal ratio with a sweet taste that can be consumed by people of all ages and genders through numerous embodiments.

[0042] Accordingly, the present invention uses 1 to 10 weight percent of the Godeulppaegi powder relative to the total weight, 70 to 75 weight percent of the sugar powder relative to the total weight, and 4 to 6 weight percent of the vitamin C powder.

[0043] In the present invention, it is preferable to use 60% by weight of the glucose contained in the sugar powder relative to the total weight and 1.38% by weight of the starch hydrolysate relative to the total weight.

[0044] In addition, the above starch hydrolysate contains maltodextrin.

[0045] The above vitamin and mineral mixed powder comprises calcium phosphate, ferrous fumarate, nicotinamide, zinc oxide, vitamin A, vitamin E, vitamin B1 hydrochloride, vitamin B2, vitamin B6 hydrochloride, and folic acid, and in the present invention, 0.005 to 0.02 weight% of the above vitamin and mineral mixed powder is used relative to the total weight.

[0046] In addition, the above amino acid mixed powder includes L-methionine, L-tryptophan, L-glutamine, L-proline, and glycine, and in the present invention, 0.005 to 0.02 weight% is used relative to the total weight of the above amino acid mixed powder.

[0047] In addition, the above seven berry mixed powder includes blackberry powder, blackcurrant powder, blueberry powder, strawberry powder, raspberry powder, cranberry powder, and acai berry powder, and in the present invention, 2.5 to 7.5 weight percent of the above seven berry mixed powder is used relative to the total weight.

[0048] In addition, the sweetener mixed powder is a nutrient comprising xylitol, magnesium stearate, anhydrous citric acid, enzyme-treated stevia, and synthetic flavoring, and in the present invention, the amino acid mixed powder is used in an amount of 10 to 12 weight percent relative to the total weight.

[0049] Specifically, based on the total weight, 6% by weight of xylitol, 1% by weight of magnesium stearate, 2% by weight of anhydrous citric acid, 0.6% by weight of enzyme-treated stevia, and 2% by weight of synthetic flavoring are used.

[0050] Next, the mixed Godeulppaegi powder, sugar powder, vitamin C powder, vitamin and mineral mixed powder, amino acid mixed powder, seven berry mixed powder, and sweetener mixed powder are placed in a tablet press and compressed.

[0051] "Tablet compression" is a term primarily used in the pharmaceutical industry regarding the process of making tablets by compressing drug raw materials, and the aforementioned tablet compression machine is a machine that compresses materials into a specific size and shape.

[0052] In addition, the tablets were pressed using the Rotary Machine KT-30 with the above-mentioned tablet press, and pressed at 10 to 40 RPM.

[0053] In addition, the active ingredients contained in the above-mentioned Godeulppaegi and other nutritional components such as vitamin C, vitamins and minerals, and amino acids are compressed into a tablet formulation with a diameter of 10 to 20 mm so that people can conveniently consume them by chewing.

[0054] Next, the manufacturing of the Godeulppaegi vitamin is completed by packaging the above-mentioned tablet-form Godeulppaegi vitamin in a dedicated storage bottle.

[0055] FIG. 2 is a drawing showing a photograph of a Godeulppaegi vitamin product according to an embodiment of the present invention. By referring to FIG. 2, the external appearance or packaging state of the Godeulppaegi vitamin tablet can be confirmed.

[0056] The Godeulppaegi vitamin product of Fig. 2 has a weight of 1,000 mg per Godeulppaegi vitamin tablet, and each Godeulppaegi vitamin tablet contains 50 mg of Godeulppaegi powder.

[0057] Meanwhile, Figure 3 is a figure showing the results of analyzing the vitamin C content contained in Godeulppaegi vitamin according to one embodiment of the present invention using HPLC. The results are obtained by taking 0.1804g of the Godeulppaegi vitamin, diluting it in 50mL of a pretreatment solvent, extracting it with ultrasound, and analyzing the vitamin C content at HPLC-DAD 254nm.

[0058] As a result of the analysis, the vitamin C content contained in the above Godeulppaegi vitamin was detected to be 198 ppm, which corresponds to 123% of the product standard amount.

[0059] In addition, Figure 4 is a diagram showing the results of a microbial test of Godeulppaegi vitamin according to an embodiment of the present invention. The microbial test is performed by taking 25g of Godeulppaegi vitamin as a sample, dissolving the solution in 250mL of NaCl solution, diluting the solution 10-fold, dispensing 1mL of the diluted solution onto a dry film medium, and then incubating at 36℃ for 24 hours to determine whether microorganisms grow.

[0060] The left side of Fig. 4 shows the test results using a dry film medium composed of general bacteria, and the right side of Fig. 4 shows the test results using a dry film medium composed of coliform bacteria.

[0061] Referring to Fig. 4, it can be seen that no microorganisms were detected in either the general bacterial group or the coliform group for each 1 mL of the NaCl solution containing the Godeulppaegi vitamin.

[0063] Below, the efficacy of the Godeulppaegi used in the present invention will be further explained by using the results of evaluating the anti-inflammatory, antihypertensive, antioxidant, and anti-cholesterol activities as examples.

[0064] Figures 5 and 6 show the results of experiments on the efficacy of *Godeulppaegi* according to an embodiment of the present invention. Figure 5 shows the results of evaluating anti-inflammatory activity, antihypertensive activity, and antioxidant activity using a *Godeulppaegi* specimen, and Figure 6 shows the results of evaluating anti-cholesterol activity using a *Godeulppaegi* specimen.

[0065] Anti-inflammatory activity refers to the efficacy of calming and resisting inflammatory responses, which are the main causes of tissue damage and aging. In the embodiment of the present invention, the anti-inflammatory activity result is measured by using the NO (Nitric Oxide) assay method to determine the anti-inflammatory activity of the Godeulppaegi specimen.

[0066] In addition, NO is known as a major inflammatory agent produced by immune cells during the body's inflammatory process.

[0067] In addition, the cells used for the evaluation of anti-inflammatory activity in Fig. 5 are RAW264.7 macrophages obtained from KCLB (Korean Cell Line Bank, Seoul, Korea), which were subcultured at 37°C and 5% CO2 using DMEM medium containing 100 units / mL of antibiotics and 10% FBS.

[0068] In addition, 1×10⁶ RAW264.7 cells passaged 5 Cells / well are counted and cultured in a 48-well plate for 24 hours, and then used for the evaluation of the anti-inflammatory activity.

[0069] In addition, the anti-inflammatory activity evaluation is performed using LPS (Lipopolysaccharides) as an agent to intentionally induce inflammation in the RAW264.7 cells. The existing medium in the 48-well plate is removed, and each culture medium containing 0.5 μg / mL of LPS (Lipopolysaccharide) and the Godeulppaegi sample at different concentrations is dispensed into the 48-well plate in which the RAW264.7 cells are cultured and cultured for 72 hours. Then, Griess reagent is added to the culture medium in the 48-well plate and reacted for 10 minutes, after which the absorbance is measured at 540 nm and a standard curve is constructed using sodium nitrate to calculate the NO content, thereby evaluating the anti-inflammatory activity.

[0070] At this time, the concentrations of the above Godeulppaegi samples are 0.05 mg / mL, 0.1 mg / mL, and 0.2 mg / mL, and for comparative evaluation, an onion extract at a concentration of 0.05 mg / mL is treated and used as a comparison group, and a well treated with a culture medium mixed only with LPS is used as a positive control group.

[0071] The graph showing the anti-inflammatory activity of *Godeulppaegi* in Figure 5 has the negative control group, the positive control group, the *Godeulppaegi* specimen, and the comparison group on the x-axis, and the NO concentration on the y-axis.

[0072] Referring to Figure 5, the Godeulppaegi specimens at concentrations of 0.05 mg / mL, 0.1 mg / mL, and 0.2 mg / mL have lower NO concentrations overall compared to the positive control group, so it can be confirmed that Godeulppaegi has anti-inflammatory activity.

[0073] In addition, it can be confirmed that the above 0.1 mg / mL Godeulppaegi sample shows similar results to the above comparison group using an onion extract at a concentration of 0.05 mg / mL.

[0074] Meanwhile, the antihypertensive activity using the above-mentioned Godeulppaegi specimen is evaluated by confirming the inhibitory effect on ACE (Angiotensin I converting enzyme), an enzyme associated with blood pressure elevation.

[0075] In addition, the above ACE inhibitory effect is measured using a commercially available ACE kit (Dojindo Molecular Technologies, Inc.).

[0076] To this end, 0.02 mL of substrate included in the ACE kit and 0.02 μL of enzyme working solution were added to each of the 0.2 mg / mL, 1 mg / mL, and 2 mg / mL samples of *Godeulppaegi*, respectively, mixed, and then evaluated using a reaction solution that was reacted at 37°C for 1 hour.

[0077] Next, 0.2 mL of the indicator working solution is added to the above reaction solution and reacted at room temperature for 10 minutes, after which the absorbance is measured at 450 nm using a microplate reader.

[0078] At this time, the evaluation of the antihypertensive activity of the Godeulppaegi specimens by concentration is calculated by applying the absorbance of the control group measured by the control group and the absorbance of the sample-added group measured by the test group containing the Godeulppaegi specimens by concentration using Equation 1 below, and is expressed as the average value after measuring the same test solution three times.

[0080] [Equation 1]

[0081]

[0083] The graph in Figure 5 showing the antihypertensive activity of *Godeulppaeji* has the above *Godeulppaeji* sample on the x-axis and the y-axis represents ACE inhibitory activity, i.e., antihypertensive activity.

[0084] Referring to Figure 5, the 0.2 mg / mL Godeulppaegi sample showed 61.9% antihypertensive activity, the 1 mg / mL Godeulppaegi sample showed 80.9%, and the 2 mg / mL Godeulppaegi sample showed 82.3% ACE inhibitory activity, confirming the antihypertensive activity of Godeulppaegi.

[0085] Meanwhile, the above-mentioned antioxidant activity evaluation is a method for evaluating whether an antioxidant substance removes free radicals, which attack normal cells in the body and act as a cause of aging or various diseases.

[0086] In addition, the above antioxidant activity can be evaluated by measuring DPPH (2,2-Diphenyl-1-picrylhydrazyl) radical scavenging ability and ABTS (2,2'-Azino-bis(3-ethylbenzothiazoline-6-sulfonic acid)) radical scavenging ability.

[0087] As shown in Equations 2 and 3 below, the DPPH radical scavenging ability evaluation calculates the amount of reactive oxygen species scavenged by the antioxidant substance donating electrons to DPPH free radicals as a percentage, and the ABTS radical scavenging ability calculates the amount of ABTS cations removed by the antioxidant substance as a percentage.

[0089] [Equation 2]

[0090]

[0092] [Equation 3]

[0093]

[0095] To this end, the above DPPH radical scavenging activity test is performed by adding 0.01 mL each of Godeulppaegi samples of 0.5 mg / mL, 1 mg / mL, and 2 mg / mL to 0.19 mL of 0.1 mM DPPH solution, reacting at room temperature for 30 minutes, centrifuging, and measuring the absorbance of the supernatant at 517 nm.

[0096] Next, the absorbance of the control group measured using the above Equation 2 and the absorbance of the sample addition group measured using the above concentration of the Godeulppaegi sample are applied.

[0097] In addition, the ABTS radical scavenging ability test is performed by mixing a solution of 7 mM ABTS and 2.45 mM Potassium persulfate with a 100 mM Potassium phosphate solution (pH 7.4) to form ABTS cations, adding 0.19 mL of the ABTS radical solution containing the ABTS cations and 0.01 mL each of Godeulppaegi samples at 2.5 mg / mL, 5 mg / mL, and 10 mg / mL to a 96-well plate, mixing well, leaving at room temperature for 6 minutes, and then measuring the absorbance at 734 nm.

[0098] Next, the absorbance of the control group measured using the above Equation 3 and the absorbance of the sample added group measured using the test group containing the above concentration of Godeulppaegi specimens are applied to calculate.

[0099] Referring to Fig. 5, the x-axis of the graph showing the antioxidant activity (DPPH radical scavenging ability) of the Godeulppaegi sample is the Godeulppaegi sample, and the y-axis is the DPPH radical scavenging ability, i.e., the antioxidant activity.

[0100] In addition, the DPPH radical scavenging activity of the 0.5 mg / mL Godeulppaegi sample was 10.7%, the DPPH radical scavenging activity of the 1 mg / mL Godeulppaegi sample was 12.3%, and the DPPH radical scavenging activity of the 2 mg / mL Godeulppaegi sample was 23.6%, showing that the DPPH radical scavenging activity increased as the concentration of the Godeulppaegi sample increased.

[0101] In addition, the graph in Figure 5 showing the antioxidant activity (ABTS radical scavenging ability) of the Godeulppaegi sample has the x-axis representing the Godeulppaegi sample and the y-axis representing the ABTS radical scavenging ability, i.e., the antioxidant activity.

[0102] In addition, the ABTS radical scavenging activity of the above 2.5 mg / mL Godeulppaegi sample was 14.2%, the ABTS radical scavenging activity of the above 5 mg / mL Godeulppaegi sample was 77.7%, and the ABTS radical scavenging activity of the above 10 mg / mL Godeulppaegi sample was 97.7%, showing results in which the ABTS radical scavenging activity increased significantly as the concentration of the above Godeulppaegi sample increased.

[0103] Meanwhile, anti-cholesterol activity is evaluated by assessing the inhibitory activity of HMC-CoA Reductase, an enzyme that regulates the rate of cholesterol synthesis in hepatocytes.

[0104] For evaluation, 0.005 mL of each 0.25 mg / mL and 0.5 mg / mL Godeulppaegi sample is mixed with 0.004 mL of NADPH, 0.012 mL of HMG-CoA, and 0.002 mL of HMG reductase, and the change in absorbance is observed kinetically while mixing for 20 minutes.

[0105] In addition, anti-cholesterol activity is calculated as a percentage using Equation 4 below.

[0107] [Equation 4]

[0108]

[0110] Referring to Figure 6, the graph showing the anti-cholesterol activity of *Godeulppaegi* has the *Godeulppaegi* sample on the x-axis and the HMG-CoA redutase activity inhibition rate on the y-axis.

[0111] In addition, the anti-cholesterol activity of the 0.25 mg / mL Godeulppaegi sample was 6.4%, and the anti-cholesterol activity of the 0.5 mg / mL Godeulppaegi sample was 18.2%, showing that the anti-cholesterol activity increased as the concentration of the Godeulppaegi sample increased.

[0112] Overall, it can be confirmed that as the concentration of the above Godeulppaegi sample increases, the anti-inflammatory, antihypertensive, antioxidant, and anti-cholesterol activities increase.

[0114] As described above, the present invention has been illustrated and explained with reference to embodiments, but it is not limited to the above-mentioned embodiments, and various changes and modifications may be made by those skilled in the art within the scope of the invention without departing from the spirit of the invention.

Claims

Claim 1 A step of cultivating and harvesting Godeulppaegi; a step of washing the harvested Godeulppaegi with water and sun-drying it; a step of hot-air drying the Godeulppaegi; a step of grinding the Godeulppaegi into Godeulppaegi powder; a step of sterilizing the Godeulppaegi powder; a vitamin and mineral mixed powder composed of the Godeulppaegi powder, glucose, and starch hydrolysate; vitamin C powder, disodium calcium phosphate, ferrous fumarate, nicotinamide, zinc oxide, vitamin A, vitamin C, vitamin E, vitamin B1 hydrochloride, vitamin B2, vitamin B6 hydrochloride, and folic acid; an amino acid mixed powder composed of L-methionine, L-tryptophan, L-glutamine, L-proline, and glycine; a seven-berry mixed powder composed of blackberry powder, blackcurrant powder, blueberry powder, strawberry powder, raspberry powder, cranberry powder, and acai berry powder; xylitol, magnesium stearate, anhydrous citric acid, and enzyme treatment A method for manufacturing Godeulppaegi vitamin comprising the steps of: weighing and mixing a sweetener mixture powder consisting of stevia and synthetic flavoring; compressing into tablets; and packaging. Claim 2 A method for producing Godeulppaegi vitamin according to claim 1, characterized in that the Godeulppaegi powder comprises 1 to 10 weight% of the total weight, the sugar powder comprises 70 to 75 weight% of the total weight, the vitamin C powder comprises 4 to 6 weight% of the total weight, the vitamin and mineral mixed powder comprises 0.005 to 0.02 weight% of the total weight, the amino acid mixture comprises 0.005 to 0.02 weight% of the total weight, the seven berry mixed powder comprises 2.5 to 7.5 weight% of the total weight, and the sweetener mixed powder comprises 10 to 12 weight% of the total weight. Claim 3 A method for manufacturing Godeulppaegi vitamin according to claim 2, wherein the washing step comprises washing the Godeulppaegi with water for 5 to 15 minutes and repeating the washing twice, the sun-drying step comprises drying in sunlight for 4 to 6 hours, the hot-air drying step comprises drying at a temperature of 65 to 75°C for 12 to 48 hours, the grinding step comprises grinding the Godeulppaegi after the hot-air drying is completed to a size of 70 to 90 mesh, and the sterilization step comprises sterilizing at a temperature of 90 to 99°C for 12 to 48 hours. Claim 4 In claim 3, the Godeulppaegi comprises having a higher NO (Nitric Oxide) inhibitory activity compared to a positive control treated only with LPS at a concentration of 0.05 to 0.2 mg / mL of the sample containing the Godeulppaegi, exhibiting 60 to 83% ACE (Angiotensin I Converting Enzyme) inhibitory activity at a concentration of 0.2 to 2 mg / mL of the sample containing the Godeulppaegi, exhibiting 10 to 24% DPPH (2,2-Diphenyl-1-picrylhydrazyl) radical scavenging activity at a concentration of 0.5 to 2 mg / mL of the sample containing the Godeulppaegi, and exhibiting 10 to 98% ABTS (2,2'-Azino-bis(3-ethylbenzothiazoline-6-sulfonic acid)) radical scavenging activity at a concentration of 2.5 to 10 mg / mL of the sample containing the Godeulppaegi, and A method for producing Godeulppaegi vitamin characterized by having anti-inflammatory, antihypertensive, antioxidant, and anti-cholesterol activities, including exhibiting 6 to 18% anti-cholesterol activity per 0.25 to 0.5 mg / mL of a sample containing Godeulppaegi. Claim 5 Godeulppaegi vitamin comprising the method for manufacturing Godeulppaegi vitamin according to any one of claims 1 to 4.

Images